259 related articles for article (PubMed ID: 21766440)
41. Fetal risks of maternal pharmacotherapy: identifying signals.
Koren G
Handb Exp Pharmacol; 2011; 205():285-94. PubMed ID: 21882117
[TBL] [Abstract][Full Text] [Related]
42. Medication use in the neonatal intensive care unit: current patterns and off-label use of parenteral medications.
Kumar P; Walker JK; Hurt KM; Bennett KM; Grosshans N; Fotis MA
J Pediatr; 2008 Mar; 152(3):412-5. PubMed ID: 18280851
[TBL] [Abstract][Full Text] [Related]
43. Pregnancy exposure registries.
Kennedy DL; Uhl K; Kweder SL
Drug Saf; 2004; 27(4):215-28. PubMed ID: 15003034
[TBL] [Abstract][Full Text] [Related]
44. Counseling regarding pregnancy--related drug exposures by family physicians in Ontario.
Goodwin J; Rieder S; Rieder MJ; Matsui D
Can J Clin Pharmacol; 2007; 14(1):e58-69. PubMed ID: 17314415
[TBL] [Abstract][Full Text] [Related]
45. National patterns of medication use during pregnancy.
Lee E; Maneno MK; Smith L; Weiss SR; Zuckerman IH; Wutoh AK; Xue Z
Pharmacoepidemiol Drug Saf; 2006 Aug; 15(8):537-45. PubMed ID: 16700083
[TBL] [Abstract][Full Text] [Related]
46. Food and Drug Administration monitoring of adverse drug reactions.
Sills JM; Tanner LA; Milstien JB
Am J Hosp Pharm; 1986 Nov; 43(11):2764-70. PubMed ID: 3799612
[TBL] [Abstract][Full Text] [Related]
47. Interpretations of a teratogen warning symbol.
Daniel KL; Goldman KD; Lachenmayr S; Erickson JD; Moore C
Teratology; 2001 Sep; 64(3):148-53. PubMed ID: 11514945
[TBL] [Abstract][Full Text] [Related]
48. Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers.
Bennett CL; Nebeker JR; Yarnold PR; Tigue CC; Dorr DA; McKoy JM; Edwards BJ; Hurdle JF; West DP; Lau DT; Angelotta C; Weitzman SA; Belknap SM; Djulbegovic B; Tallman MS; Kuzel TM; Benson AB; Evens A; Trifilio SM; Courtney DM; Raisch DW
Arch Intern Med; 2007 May; 167(10):1041-9. PubMed ID: 17533207
[TBL] [Abstract][Full Text] [Related]
49. Smoke, alcohol consumption and illicit drug use in an Italian population of pregnant women.
De Santis M; De Luca C; Mappa I; Quattrocchi T; Angelo L; Cesari E
Eur J Obstet Gynecol Reprod Biol; 2011 Nov; 159(1):106-10. PubMed ID: 21831510
[TBL] [Abstract][Full Text] [Related]
50. Prescription medications for use in pregnancy-perspective from the US Food and Drug Administration.
Wesley BD; Sewell CA; Chang CY; Hatfield KP; Nguyen CP
Am J Obstet Gynecol; 2021 Jul; 225(1):21-32. PubMed ID: 34215352
[TBL] [Abstract][Full Text] [Related]
51. Teratogenic mechanisms of medical drugs.
van Gelder MM; van Rooij IA; Miller RK; Zielhuis GA; de Jong-van den Berg LT; Roeleveld N
Hum Reprod Update; 2010; 16(4):378-94. PubMed ID: 20061329
[TBL] [Abstract][Full Text] [Related]
52. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
[TBL] [Abstract][Full Text] [Related]
53. [Over the counter medication in pregnant women].
Mikou S; Buire AC; Trenque T
Therapie; 2008; 63(6):415-8. PubMed ID: 19236832
[TBL] [Abstract][Full Text] [Related]
54. Trends in pregnancy labeling and data quality for US-approved pharmaceuticals.
Mazer-Amirshahi M; Samiee-Zafarghandy S; Gray G; van den Anker JN
Am J Obstet Gynecol; 2014 Dec; 211(6):690.e1-11. PubMed ID: 24912093
[TBL] [Abstract][Full Text] [Related]
55. Teratogenic exposures.
Običan S; Scialli AR
Am J Med Genet C Semin Med Genet; 2011 Aug; 157C(3):150-69. PubMed ID: 21766437
[TBL] [Abstract][Full Text] [Related]
56. Systematic procedure for the classification of proven and potential teratogens for use in research.
Eltonsy S; Martin B; Ferreira E; Blais L
Birth Defects Res A Clin Mol Teratol; 2016 Apr; 106(4):285-97. PubMed ID: 26969841
[TBL] [Abstract][Full Text] [Related]
57. Structure-Activity Relationship (SAR) Model for Predicting Teratogenic Risk of Antiseizure Medications in Pregnancy by Using Support Vector Machine.
Kang L; Duan Y; Chen C; Li S; Li M; Chen L; Wen Z
Front Pharmacol; 2022; 13():747935. PubMed ID: 35281912
[TBL] [Abstract][Full Text] [Related]
58. The 2015 US Food and Drug Administration Pregnancy and Lactation Labeling Rule.
Brucker MC; King TL
J Midwifery Womens Health; 2017 May; 62(3):308-316. PubMed ID: 28556499
[TBL] [Abstract][Full Text] [Related]
59. A comparison of pregnancy prevention programmes in Europe.
Crijns I; Zomerdijk I; Sturkenboom M; de Jong-van den Berg L; Straus S
Expert Opin Drug Saf; 2014 Apr; 13(4):411-20. PubMed ID: 24506812
[TBL] [Abstract][Full Text] [Related]
60. Report of the Teratology Society Public Affairs Committee symposium on FDA classification of drugs.
Friedman JM
Teratology; 1993 Jul; 48(1):5-6. PubMed ID: 8102499
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
